ReviewNanoscale advances2023
Recent strategies for constructing hierarchical multicomponent nanoparticles/metal-organic framework hybrids and their applications.
Review in Nanoscale advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid nanoparticles with unique tailored morphologies and compositions can be utilized for numerous applications owing to their combination of inherent properties as well as the structural and supportive functions of each component. Controlled encapsulation of nanoparticles within nanospaces (NPNSs) of metal-organic frameworks (MOFs) (denoted as NPNS@MOF) can generate a large number of hybrid nanomaterials, facilitating superior activity in targeted applications. In this review, recent strategies for the fabrication of NPNS@MOFs with a hierarchical architecture, tailorability, unique intrinsic properties, and superior catalytic performance are summarized. In addition, the latest and most important examples in this sector are emphasized since they are more conducive to the practical applicability of NPNS@MOF nanohybrids.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.